Virtual screening of dipeptidyl peptidase-4 inhibitors using quantitative structure-activity relationship-based artificial intelligence and molecular docking of hit compounds

[1]  M. A. Chamjangali,et al.  Combination of least absolute shrinkage and selection operator with Bayesian Regularization artificial neural network (LASSO-BR-ANN) for QSAR studies using functional group and molecular docking mixed descriptors , 2020 .

[2]  M. Ramesh,et al.  Quantitative Structure-Activity Relationship (QSAR) Studies for the Inhibition of MAOs. , 2020, Combinatorial chemistry & high throughput screening.

[3]  K. Qu,et al.  Virtual Screening of the multi-pathway and multi-gene regulatory molecular mechanism of Dachengqi decoction in the treatment of stroke Based on Network Pharmacology. , 2020, Combinatorial chemistry & high throughput screening.

[4]  Gabriela Bitencourt-Ferreira,et al.  Taba: A Tool to Analyze the Binding Affinity , 2019, J. Comput. Chem..

[5]  Ming Hu,et al.  Evaluating explorative prediction power of machine learning algorithms for materials discovery using k-fold forward cross-validation , 2020, Computational Materials Science.

[6]  Zefeng Wang,et al.  Virtual Screening of Potential Anti-fatigue Mechanism for Polygonati Rhizoma Based on Network Pharmacology. , 2019, Combinatorial chemistry & high throughput screening.

[7]  Gabriela Bitencourt-Ferreira,et al.  Application of Machine Learning Techniques to Predict Binding Affinity for Drug Targets. A Study of Cyclin-Dependent Kinase 2. , 2019, Current medicinal chemistry.

[8]  R. Huber,et al.  Improvement of Protein Crystal Diffraction Using Post-Crystallization Methods: Infrared Laser Radiation Controls Crystal Order , 2019 .

[9]  K. Makrilakis.  The Role of DPP-4 Inhibitors in the Treatment Algorithm of Type 2 Diabetes Mellitus: When to Select, What to Expect , 2019, International journal of environmental research and public health.

[10]  B. Gallwitz.  Clinical Use of DPP-4 Inhibitors , 2019, Front. Endocrinol..

[11]  Z Y Algamal,et al.  A QSAR model for predicting antidiabetic activity of dipeptidyl peptidase-IV inhibitors by enhanced binary gravitational search algorithm , 2019, SAR and QSAR in environmental research.

[12]  Evan Bolton,et al.  PubChem 2019 update: improved access to chemical data , 2018, Nucleic Acids Res..

[13]  Jamal Shamsara,et al.  A random forest model to predict the activity of a large set of soluble epoxide hydrolase inhibitors solely based on a set of simple fragmental descriptors. , 2019, Combinatorial chemistry & high throughput screening.

[14]  E. Bonora,et al.  Ten years of experience with DPP-4 inhibitors for the treatment of type 2 diabetes mellitus , 2019, Acta Diabetologica.

[15]  Wanqiang Liu,et al.  An Improved Quantitative Structure Property Relationship Model for Predicting Thermal Conductivity of Liquid Aliphatic Alcohols , 2018 .

[16]  Eugene N. Muratov,et al.  QSAR-Based Virtual Screening: Advances and Applications in Drug Discovery , 2018, Front. Pharmacol..

[17]  Jingsheng Shi,et al.  Computational QSAR model combined molecular descriptors and fingerprints to predict HDAC1 inhibitors. , 2018, Medecine sciences : M/S.

[18]  Adrià Cereto-Massagué,et al.  Activity and selectivity cliffs for DPP‐IV inhibitors: Lessons we can learn from SAR studies and their application to virtual screening , 2018, Medicinal research reviews.

[19]  R. Huber,et al.  Structures and mechanism of dipeptidyl peptidases 8 and 9, important players in cellular homeostasis and cancer , 2018, Proceedings of the National Academy of Sciences.

[20]  Samina Kausar,et al.  An automated framework for QSAR model building , 2018, Journal of Cheminformatics.

[21]  Rajesh Kumar Tiwari,et al.  Prediction of Drug-Plasma Protein Binding Using Artificial Intelligence Based Algorithms. , 2017, Combinatorial chemistry & high throughput screening.

[22]  Agnieszka Chylewska,et al.  Metallopharmaceuticals in Therapy - A New Horizon for Scientific Research. , 2017, Current medicinal chemistry.

[23]  T. Stanojković,et al.  Antidiabetics: Structural Diversity of Molecules with a Common Aim. , 2017, Current medicinal chemistry.

[24]  Md. Asiful Islam,et al.  Updates on Managing Type 2 Diabetes Mellitus with Natural Products: Towards Antidiabetic Drug Development. , 2016, Current medicinal chemistry.

[25]  Yue Kong,et al.  QSAR models for predicting the bioactivity of Polo-like Kinase 1 inhibitors , 2017 .

[26]  Jun Xu,et al.  Predicting DPP-IV inhibitors with machine learning approaches , 2017, Journal of Computer-Aided Molecular Design.

[27]  Vesko Milenković,et al.  QSAR study of dipeptidyl peptidase-4 inhibitors based on the Monte Carlo method , 2017, Medicinal Chemistry Research.

[28]  George Papadatos,et al.  The ChEMBL database in 2017 , 2016, Nucleic Acids Res..

[29]  Danishuddin,et al.  Descriptors and their selection methods in QSAR analysis: paradigm for drug design. , 2016, Drug discovery today.

[30]  Faisal Saeed,et al.  Bioactive Molecule Prediction Using Extreme Gradient Boosting , 2016, Molecules.

[31]  H. Ueno,et al.  Trelagliptin (SYR-472, Zafatek), Novel Once-Weekly Treatment for Type 2 Diabetes, Inhibits Dipeptidyl Peptidase-4 (DPP-4) via a Non-Covalent Mechanism , 2016, PloS one.

[32]  Gang Fu,et al.  PubChem Substance and Compound databases , 2015, Nucleic Acids Res..

[33]  Celeste B. Burness.  Omarigliptin: First Global Approval , 2015, Drugs.

[34]  K. McKeage.  Trelagliptin: First Global Approval , 2015, Drugs.

[35]  George Papadatos,et al.  ChEMBL web services: streamlining access to drug discovery data and utilities , 2015, Nucleic Acids Res..

[36]  Kunal Roy,et al.  A Primer on QSAR/QSPR Modeling: Fundamental Concepts , 2015 .

[37]  Z. Shen,et al.  Establishment of a dipeptidyl peptidases (DPP) 8/9 expressing cell model for evaluating the selectivity of DPP4 inhibitors. , 2015, Journal of pharmacological and toxicological methods.

[38]  Rosaria Silipo,et al.  Seven Techniques for Data Dimensionality Reduction Missing Values , Low Variance Filter , High Correlation Filter , PCA , Random Forests , Backward Feature Elimination , and Forward Feature Construction , 2015 .

[39]  T. Poulos,et al.  Nitric Oxide Synthase Inhibitors That Interact with Both Heme Propionate and Tetrahydrobiopterin Show High Isoform Selectivity , 2014, Journal of medicinal chemistry.

[40]  Kathy Lyons,et al.  Omarigliptin (MK-3102): a novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes. , 2014, Journal of medicinal chemistry.

[41]  M. Ghate,et al.  Recent approaches to medicinal chemistry and therapeutic potential of dipeptidyl peptidase-4 (DPP-4) inhibitors. , 2014, European journal of medicinal chemistry.

[42]  J. Dearden,et al.  QSAR modeling: where have you been? Where are you going to? , 2014, Journal of medicinal chemistry.

[43]  Thorsten Meinl,et al.  KNIME-CDK: Workflow-driven cheminformatics , 2013, BMC Bioinformatics.

[44]  Wencong Lu,et al.  Predicting the DPP-IV Inhibitory Activity pIC50 Based on Their Physicochemical Properties , 2013, BioMed research international.

[45]  Wencong Lu,et al.  QSAR studies on pyrrolidine amides derivatives as DPP-IV inhibitors for type 2 diabetes , 2013, Medicinal Chemistry Research.

[46]  E. Schuck,et al.  A transcellular assay to assess the P-gp inhibition in early stage of drug development. , 2013, Drug metabolism letters.

[47]  Qin Tong,et al.  Molecular fingerprint-based artificial neural networks QSAR for ligand biological activity predictions. , 2012, Molecular pharmaceutics.

[48]  Inaki Morao,et al.  Drug discovery applications for KNIME: an open source data mining platform. , 2012, Current topics in medicinal chemistry.

[49]  Michael M. Mysinger,et al.  Directory of Useful Decoys, Enhanced (DUD-E): Better Ligands and Decoys for Better Benchmarking , 2012, Journal of medicinal chemistry.

[50]  John P. Overington,et al.  ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..

[51]  S. Rees,et al.  Principles of early drug discovery , 2011, British journal of pharmacology.

[52]  A. Jain,et al.  Validation of QSAR Models-Strategies and Importance , 2011 .

[53]  Holger Fischer,et al.  Discovery of carmegliptin: a potent and long-acting dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. , 2010, Bioorganic & medicinal chemistry letters.

[54]  Thorsten Meinl,et al.  KNIME - the Konstanz information miner: version 2.0 and beyond , 2009, SKDD.

[55]  M. Pal,et al.  Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes. , 2009, Bioorganic & medicinal chemistry.

[56]  Chong Hak Chae,et al.  Docking-based 3D-QSAR study for selectivity of DPP4, DPP8, and DPP9 inhibitors. , 2007, Bioorganic & medicinal chemistry letters.

[57]  D. Kassel,et al.  Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. , 2007, Journal of medicinal chemistry.

[58]  Y. Martin,et al.  Do structurally similar molecules have similar biological activity? , 2002, Journal of medicinal chemistry.

[59]  A. Tropsha,et al.  Beware of q2! , 2002, Journal of molecular graphics & modelling.

[60]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[61]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings , 1997 .